Across TCGA pan-cancer cohorts, ZNRD1ASP Mutation is linked to patient survival in 2 of 34 cancer types, making it a survival-associated ZNRD1ASP data layer compared with 23 for mass-spec protein.

The strongest signal is observed in lung adenocarcinoma (LUAD), where higher ZNRD1ASP Mutation is associated with worse overall survival. In most high-consensus cancer types, elevated ZNRD1ASP expression acts as an unfavorable survival marker.

LUAD and PRAD are the cancer types where ZNRD1ASP Mutation most reproducibly stratifies survival.

Mutation survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
LUAD	OS	Median	III,IV	0.147	0.679	.001	21	view →
PRAD	DFS	Median	All	0.085	0.774	<.001	6	view →

Pink = unfavorable, green = favorable. Showing the 2 strongest of 2 lineages.

Exploration

Same gene, other analysis: ZNRD1ASP tumor-vs-normal RNA expression · all ZNRD1ASP data types